Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 66% Improvement Relative Risk Time to discharge 29% Time to clinical cure 43% Time to viral clearance 27% Favipiravir  Udwadia et al.  EARLY TREATMENT  RCT Is early treatment with favipiravir beneficial for COVID-19? RCT 148 patients in India (May - July 2020) Faster recovery (p=0.069) and viral clearance (p=0.098), not sig. c19early.org Udwadia et al., Int. J. Infectious Dis.., Nov 2020 Favors favipiravir Favors control

Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial

Udwadia et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.142, CTRI/2020/05/025114
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT with 75 favipiravir patients and 75 control patients showing improved recovery with treatment.
risk of death, 66.4% lower, RR 0.34, p = 1.00, treatment 0 of 73 (0.0%), control 1 of 75 (1.3%), NNT 75, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
time to discharge, 28.9% lower, HR 0.71, p = 0.07, treatment 75, control 72, inverted to make HR<1 favor treatment.
time to clinical cure, 42.8% lower, HR 0.57, p = 0.02, treatment 75, control 72, inverted to make HR<1 favor treatment.
time to viral clearance, 26.8% lower, HR 0.73, p = 0.10, treatment 75, control 72, inverted to make HR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Udwadia et al., 16 Nov 2020, Randomized Controlled Trial, India, peer-reviewed, 11 authors, study period 14 May, 2020 - 3 July, 2020, trial CTRI/2020/05/025114.
This PaperFavipiravirAll
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
Zarir F Udwadia, Pawan Singh, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Amol Pendse, Jatin Kadam, Wen Wu, Cynthia F Caracta, Monika Tandon
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.142
To assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 . Methods: In this randomized, open-label, parallel-arm, multicenter, phase 3 trial, adults (18-75 years) with RT-PCR confirmed COVID-19 and mild-to-moderate symptoms (including asymptomatic) were randomized 1:1 to oral favipiravir (day 1: 1800 mg BID and days 2À14: 800 mg BID) plus standard supportive care versus supportive care alone. The primary endpoint was time to the cessation of viral shedding; time to clinical cure was also measured. Results: From May 14 to July 3, 2020, 150 patients were randomized to favipiravir (n = 75) or control (n = 75). Median time to the cessation of viral shedding was 5 days (95% CI: 4 days, 7 days) versus 7 days (95% CI: 5 days, 8 days), P = 0.129, and median time to clinical cure was 3 days (95% CI: 3 days, 4 days) versus 5 days (95% CI: 4 days, 6 days), P = 0.030, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients. One control patient died due to worsening disease. Conclusion: The lack of statistical significance on the primary endpoint was confounded by limitations of the RT-PCR assay. Significant improvement in time to clinical cure suggests favipiravir may be beneficial in mild-to-moderate COVID-19.
Conflict of interest Monika Tandon, Pawan Singh, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Amol Pendse, and Jatin Kadam are fulltime employees of Glenmark Pharmaceuticals Limited, India. Wen Wu is a full-time employee of Glenmark Pharmaceuticals Ltd, United Kingdom. Cynthia Caracta is a full-time employee of Glenmark Pharmaceuticals Inc., USA. Zarir F Udwadia received an investigator grant from Glenmark Pharmaceuticals Limited, India, as a site principal investigator for this study. Ethical approval The protocol and informed consent form were approved by institutional/independent ethics committees and the Drugs Controller General of India (April 26, 2020) . The trial was undertaken in accordance with current guidelines of the Central Drugs Standard Control Organization, which is the National Regulatory Authority in India, the International Conference on Harmonization Good Clinical Practice, and the Declaration of Helsinki. All patients provided written informed consent. Contributions Author contributions: All authors contributed equally to this report. Zarir F Udwadia, Monika Tandon, Pawan Singh, Hanmant Barkate, Shabbir Rangwala, Amol Pendse, and Wen Wu had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Monika Tandon, Pawan Singh, Hanmant Barkate, Saiprasad Patil, and Wen Wu. Acquisition, analysis, or interpretation of data: Jatin Kadam, Amol..
References
Agrawal, Raju, Udwadia, Favipiravir: a new and emerging antiviral option in COVID-19, Med J Armed Forces India, doi:[368_TD$DIFF]10.1016/j.mjafi.2020.08.004
Buonaguro, Tagliamonte, Tornesello, Buonaguro, SARS-CoV-2 RNA polymerase as target for antiviral therapy, J Transl Med
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering
Carmo, Pereira-Vaz, Mota, Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19, J Med Virol
Chen, Huang, Cheng, Favipiravir versus Arbidol for COVID-19: a randomized clinical trial, MedRxiv, doi:10.1101/2020.03.17.20037432
Delang, Abdelnabi, Neyts, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, Antiviral Res
Doi, Hibino, Hase, A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19, Antimicrob Agents Chemother, doi:10.1128/AAC.01897-20
Dong, Hu, Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov Ther
Fu, Han, Zhu, Risk factors for viral RNA shedding in COVID-19 patients, Eur Respir J, doi:10.1183/13993003.01190-2020
Furuta, Gowen, Takahashi, Shiraki, Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci
Gogtay, Ravi, Thatte, Regulatory requirements for clinical trials in India: what academicians need to know, Indian J Anaesth
Goyal, Cardozo-Ojeda Fabian, Schiffer, Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response, Sci Adv, doi:10.1126/sciadv.abc7112
Heneghan, Onakpoya, Jones, Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data, Health Technol Assess
Ivashchenko, Dmitriev, Vostokova, AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial, Clin Infect Dis, doi:[382_TD$DIFF]10.1093/cid/ciaa1176
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic?, J Virus Erad
Qi, Yang, Jiang, Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study, Int J Infect Dis
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA
Schiffer, Johnston, Corey, Song, Zhang et al., COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus, Int J Antimicrob Agents
Spinner, Gottlieb, Criner, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Udwadia, Singh, Barkate, None, International Journal of Infectious Diseases
Udwadia, Singh, Barkate, None, International Journal of Infectious Diseases
Widders, Broom, Broom, SARS-CoV-2: the viral shedding vs infectivity dilemma, Infect Dis Health
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Xu, Chen, Yuan, Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19), Clin Infect Dis
Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit